➤ Following the golden age of antibiotic discovery, no new class of broadspectrum antibiotics was discovered for another 50 years, during which pathogens continued developing resistance to such drugs.
It is hard to discover new antibiotics. The fıeld of antiinfectives has a unique history which does not follow the expected path of knowledge leading to cures. We now know incomparably more than we did during the golden era of antibiotic discovery from the 1940s to 1960s, but seem no longer capable of developing novel therapeutics for infectious diseases. Why this anomaly? What approaches can revive antibiotic discovery?
Alexander Fleming discovered penicillin, the fırst truly successful antibiotic, when he noticed that a contaminating Penicillium fungus was killing staphylococci on a Petri dish. Finding this antibiotic was a rare event, a lucky strike, but that changed when Selman Waxman pioneered systematic screening, revolutionizing the fıeld, and with it, the entire pharmaceutical industry.
Streptomyces are the most prolifıc antibiotic producers, and Waxman recognized their potential. He introduced a simple screen which essentially replicates the accidental observation of Fleming-a Streptomyces is spot-inoculated on a plate with a lawn of a test pathogen, and a zone of growth inhibition indicates presence of an antibiotic. This method soon resulted in the discovery of streptomycin from Streptomyces gryseus. Streptomycin became the fırst antibiotic capable of treating infections by gram-negative bacteria and the fırst effective treatment for tuberculosis. The subsequent discovery of tetracycline, erythromycin, and vancomycin which followed transformed the pharmaceutical industry ( Fig. 1 ). Resistance to most antibiotics appeared soon after their discovery, but this was a relatively minor issue at the time given the constant flow of new compounds.
What happened next, however, was completely unexpected. No new class of broad-spectrum antibiotics was discovered in the next 50 years, and pathogens continue acquiring resis-tance. We now face strains of pathogens, such as Mycobacterium tuberculosis and Acinetobacteri baumannii, resistant to all known antibiotics.
A New Threat-Drug Tolerance
Advances in medicine can provide favorable environments for pathogens. Biofılms grow on indwelling devices such as catheters, orthopedic prostheses, and heart valves and are hard to kill, which is puzzling, since most chronic infections are caused by drug-susceptible pathogens.
Time-dependent killing of biofılms explains this paradox-most of the population dies, but a small number of persister cells survive. Persisters are dormant variants of regular cells that biofılms protect from the immune system. When antibiotic concentration drops, persisters revive, causing a relapsing infection.
Tuberculosis (TB) is an analogous case of a diffıcult-to-treat infection, requiring months of therapy. M. tuberculosis hides within macrophages, shielded from the immune system, and dormant cells play an important role in the recalcitrance of the infection. Bactericidal antibiotics kill by corrupting their targets-for example, fluoroquinolones convert DNA gyrase into an endonuclease, and aminoglycosides interrupt translation, which results in misfolded toxic peptides. In a dormant persister, targets are largely inactive, leading to antibiotic tolerance.
Isolated persisters overexpress toxin/antitoxin (TA) modules, pointing to a possible mechanism. Toxins inhibit important functions, such as protein synthesis, sending cells into dormancy. There are over 20 TA modules in Escherichia coli, and over 80 in M. tuberculosis. The reason for this high level of functional redundancy is unclear. We found that a particular toxin, TisB, is expressed by the SOS response during DNA damage which can be caused by fluoroquinolone antibiotics. TisB forms an ion channel in the membrane, leading to a dissipation of the pmf and ATP, producing a dormant state. Overexpression of several TA modules leads to an increase in persisters when Salmonella typhimurium enters human cells, according to Sophie Heaine and coworkers at the Imperial College London, though the nature of the trigger is unknown. This analysis shows that in persisters, we are facing an ultimate adversary-cells that evolved specifıcally to survive exposure to antimicrobials. They employ multiple redundant pathways, so that there is no realistic antipersister target; being in a low-energy, dormant state confers tolerance to all currently available antibiotics.
Unique Challenges in Discovering and Developing Antibiotics
Antibiotics are both uniquely effective and uniquely diffıcult to develop. The relative ease with which the main classes of antibiotics were discovered during the golden era is not surprising, these compounds evolved to effectively kill bacteria. Interestingly, during that same period, a number of synthetic compounds were also introduced. These still make up the main anti-TB armamentarium-isoniazid, pyrazinamide, ethambutol, and ethionamide. Metronidazole, a broad-spectrum compound effective against pathogens living under anaerobic and microaerophilic conditions, was discovered as well. Nalidixic acid, a rather weak agent, was developed into a remarkably successful class of broad-spectrum fluoroquinolones. So when the natural product pipeline dried up, many expected discovery to simply shift to synthetic compounds; however, this did not happen. Before we consider how to revive discovery, let us consider some obstacles on the way to developing new antibiotics.
• Penetration. Bacterial cells are exposed, and evolved a penetration barrier which is particularly effective in gram-negative species, in which the outer membrane is covered with negatively charged lipopolysaccharide, restricting access to hydrophobic compounds. The inner membrane blocks hydrophilic compounds, while multidrug pumps (MDRs) expel compounds that penetrate both the inner and outer membranes. The envelope is an almost impenetrable barrier for drugs.
• Toxicity. Largely due to diffıculty of penetration, effective concentrations of antibiotics are in the micromolar range, as compared to nanomolar range for therapeutics acting against targets in mammalian cells. The need for high doses leads to off-target action and toxicity. For example, aminoglycosides inhibit protein synthesis, but like other polycations, they accumulate in the lysosomes of kidney cells and cause nephrotoxicity at clinically effective doses.
• Multiple pathogens. Most antibiotics need to act against more than one pathogen, meaning that a single compound needs to effectively hit multiple members of an orthologous group. This single compound is also supposed to penetrate into cells with different sets of MDRs.
• Resistance development. Resistance by target modifıcation occurs with a probability of about 10 Ϫ9 -10 Ϫ8 . If a patient has an infection involving around 10 8 cells, resistance will cause therapy failure, making development of such an agent with a single target impractical. Compounds belonging to the main classes of currently used antibiotics-␤-lactams, aminoglycosides, macrolides, tetracyclines, and fluoroquinolones-effectively hit multiple targets, retarding development of resistance.
There are also additional barriers unrelated to science that are hard to overcome:
• Profıt. Antibiotics are victims of their own success because they produce effective cures; this, paradoxically, makes them less attractive than compounds that do not cure at all. A single dose of oritavancin is suffıcient to cure acute bacterial skin and skin structure infection caused by S. aureus; a single dose of ceftriaxone cures gonorrhea (of course, if the pathogens are susceptible). But cholesterol-lowering statins, for example, do not cure the underlying cause of disease and have to be taken for a lifetime. According to IMS Health, the best-selling antibiotic is the narrow-spectrum daptomycin (Cubist/Merck); at number 94 among all drugs, it grosses $670 million per year and sales are projected to reach $1 billion. At number 1 is Abilify, an antidepressant, making $7.7 billion per year.
• Public interest. Chronic diseases cause prolonged suffering for patients and their families. This suffering results in high public awareness; there are many foundations dedicated to combating cancer, and there are well-organized and wellfunded organizations dedicated to heart disease, Crohn's and colitis, Huntington's disease, and other conditions. Though a considerably larger number of people die from infectious diseases than from Huntington's, there is no grant-giving foundation to support work on antibiotics in general, or rallies to combat drug-resistant pathogens. As with other diseases, there are foundations focused on specifıc chronic infections, such as the Gates Foundation and the Global TB Alliance support work on tuberculosis, the Cystic Fibrosis Foundation funds work on pathogens associated with this disease, and the Global Lyme Alliance supports work on Lyme disease. It should therefore be possible to communicate the signifıcance of the larger issue of the importance of antibiotic discovery to the public. This is starting to happen in Great Britain, where the public has named antibiotic resistance among the fıve major public health priorities. The European Union established a large public-private partnership program to combat antibiotic resistance. In the United States, the President has recently issued an Executive Order for establishing a strategic program to combat antibiotic resistance (see Microbe, August 2015, p. 313).
Discovery Platforms
Since the Waxman platform for drug discovery collapsed, we have been struggling to replace it. As a result of the absence of a platform capable of reliably supplying leads, virtually all novel classes of antibiotics introduced in the last decades, including synercid, daptomycin, linezolid, and fıdaxomycin, came from resuscitating old failed leads. There is consensus that the lack of good starting compounds is the bottleneck that limits the rate of developing novel antibiotics.
Before we consider platforms that can be developed, we should determine the knowledge gaps preventing their development. There are two general categories of molecules from which antibiotics can be discovered: natural compounds and synthetics. For natural compounds, uncultured bacteria and silent operons are two untapped sources of secondary metabolites, and it would be useful to know how to access these. For synthetics, we need to know what determines the ability of a compound to penetrate into bacterial cells.
Rules of penetration. We know from long experience that screening of compound libraries does not produce good antimicrobial agents with a reasonable spectrum. The penetration problem makes rational design of inhibitors against particular targets very diffıcult. Substantial progress has been made in studying the structure of the MDR pumps of bacteria, but what we learned is not useful for designing penetrating compounds-the large, poorly structured binding sites of the model AcrAB-TolC pump of E. coli can accommodate a vast variety of chemically unrelated compounds.
Determining the rules of penetration, similar to the Lipinski rules that have been highly valuable in selecting orally bioavailable compounds that hit mammalian targets, is important. The Lipinski rules were formulated by culling useful properties from a large set of known drugs. We could similarly establish rules of penetration for antibiotics, based on a large number of compounds that penetrate into cells of gram-negative bacteria. Penetration of compounds from a random library can be measured using mass spectroscopy. Some insights into penetration rules can be gleaned even from the small set of good permeators we currently have. Highly hydrophobic compounds are well recognized by MDRs, while relatively hydrophilic compounds that are less than 450 Da are favored for penetration; zwitterions penetrate well; and it seems that inclusion of atoms that do not occur frequently in natural compounds (F, B) is good for penetration.
Once the rules are established, libraries specifically compiled for antimicrobial discovery can be synthesized. The rules would also be helpful in rational design based on the crystal structure of targets. The ligand could not only be optimized for good binding, but for penetration as well.
Reviving the Waxman platform. Uncultured bacteria, organisms that previous generations of prospectors would not have seen on their Petri dishes, are perhaps the most promising source of secondary metabolites. Based on metagenomic analysis, 99% of all microbial species on the planet are "uncultured" and do not grow under laboratory conditions, and this is a potential source of hidden antimicrobials. For example, a recently described Entotheonella sp. is responsible for making a dozen different antimicrobials present in a marine sponge. The diversity and number of compounds isolated from this single bacterium suggests that Entotheonella may represent a genus comparable to Streptomycetes in its ability to produce antimicrobials.
While Entotheonella has not yet been cultured, a general method for growing uncultured bacteria has been developed. The gist of the approach is to grow bacteria in their natural environment by introducing a marine sediment or soil sample diluted with agar between two semipermeable membranes, and placing this "diffusion chamber" back into the natural environment. Compounds diffuse freely through the chamber, and bacteria are tricked into perceiving it as their natural environment. This approach dramatically improves recovery; up to 40% of cells seeded into the chamber produce colonies.
A common cause of "uncultivability" is a need for growth factors produced by neighboring bacteria. Iron-chelating siderophores are one important group of such factors in the marine sediment environment. Repeated reinoculation from chamber to chamber results in "domestication" of a considerable proportion of uncultured microorganisms, an ability to grow on a Petri dish or in a fermenter. Interesting compounds are starting to emerge from this approach (described below), showing the promise of the platform.
Silent operons. Another untapped source of antimicrobials may be in the silent operons of producing microorganisms. The genomes of Actinomycetes show that their potential for producing secondary metabolites far surpasses their known ability. Enzymes producing antimicrobials-the polyketide synthases and nonribosomal peptide synthases-are encoded by large operons with homologies to known genes. Sequencing of the model Actinomycete Streptomycetes coelicolor showed that it codes for 20 secondary metabolites, while it is known to produce only 3 antimicrobials. S. avermitilis, the industrial producer of the antihelminthic avermectin, does not make antimicrobials at all (at least not in the lab), but according to its genome sequence, harbors 30 operons for secondary metabolites. This general theme of numerous silent operons holds for the many additional actinomycete genomes that have since been sequenced. This is a platform waiting to be developed, though we do not yet have good approaches to effıciently turn on production of silent operons.
Interesting Compounds in Discovery and Development
There are several novel compounds at different stages of development which act against new targets. The oxaborole AN3365 (Anacor/GSK) ( Fig.  2A) , an effective inhibitor of the leu-tRNA synthase, is small and fairly polar, and penetrates well into gram-negative bacteria. Though it failed in Phase II clinical trials due to resistance readily developed by mutations in the target, AN3365 is an excellent example of how to make a well-penetrating molecule and is a promising compound for combination therapy.
POL7080 (University of Zurich/Polyphor/ Roche) was discovered by a lucky accident in a program aimed at producing mimetics of the membrane-acting antimicrobial peptide (AMP) protegrin. The target is not the cytoplasmic membrane but LptD, a ␤-barrel protein of the outer membrane of P. aeruginosa (Fig. 2B ) that participates in inserting lipopolysaccharide into the outer membrane. Since the target is on the surface of the cell, there are no permeability issues. Even though it is a single target, the frequency of mutations in LptD is very low, probably because POL7080 is a large compound with multiple binding interactions. POL7080 is specifıc against P. aeruginosa, but other antimicrobials targeting the conserved LptD protein are likely to follow. Species selectivity has its advantages; for one, the compound will not harm our microbiome. POL7080 is being developed as an antipseudomonas drug and is in Phase II clinical trials.
Lassomycin (Northeastern/NovoBiotic) was identifıed in a specifıc screen of a collection of uncultured bacteria against M. tuberculosis and is produced by Lentsea, an actinomycete. Extracts were counterscreened against S. aureus, and only specifıc hits against M. tuberculosis were followed. Since virtually no natural products are specifıc against mycobacteria, this simple screen allows one to determine extracts containing novel compounds before doing any chemistry, avoiding the bottleneck of sorting known and toxic compounds that slows down natural product discovery. Lassomycin is a lasso-shaped pep-tide that inhibits the essential ClpP1P2C1 protease of M. tuberculosis while increasing its ATPase activity (Fig. 2C ). This dual mode of action kills growing and dormant cells of the pathogen. The compound also serves as proof-ofconcept for species-selective screening as a new antimicrobial discovery platform.
M64, benzamide-benzimidazole is an inhibitor of MvfR, the transcriptional activator of the P. aeruginosa quinolone quorum sensing (QS) regulon (MGH/Spero Therapeutics/Roche) (Fig.  2D ). M64 is an optimized analog of a compound identifıed in a high-throughput screen of commercial libraries (the Harvard ICCB collection). QS controls virulence in this pathogen. M64 decreased persister formation in an exponentially growing culture of P. aeruginosa and improved survival of mice with a lung and wound infection. The in vivo effıcacy of M64 was especially pronounced in combination with ciprofloxacin. Its discovery in a high-throughput screen suggests that commercial libraries that failed to produce compounds with a broad spectrum may harbor useful molecules acting against a single target. The promise of antivirulence factors lies in the expectation that they could have a low probability of resistance development. The discovery of M64 bodes well for two emerging platforms-speciesspecifıc compounds and antivirulence factors.
Acyldepsipeptide, developed by Bayer (ADEP4) but dropped due to high frequency of resistance, activates the ClpP protease ( Fig. 2E ). ClpP uses ATP-dependent chaperones to degrade misfolded proteins. Because ADEP keeps the entrance channel of ClpP open, no chaperones are needed. ADEP/ClpP is effective against energydepleted persisters since it does not require energy to cleave proteins. We found that ADEP4 kills S. aureus persisters by forcing cells to selfdigest. Since ClpP is nonessential, null mutants resistant to ADEP4 arise with high probability, but combining ADEP4 with another antibiotic solves this problem and leads to eradication of a biofılm population in vitro and in a mouse model of infection. Advanced analogs of ADEP4 are in development. ADEP is the fırst antibiotic that effectively kills persisters.
Teixobactin (NovoBiotic/Northeastern University) is a novel inhibitor of cell wall biosynthesis that was discovered in a screen of uncultured bacteria (Fig. 2F) (Microbe, April 2015, p. 138) . It is produced by Eleftheria terrae, a ␤-proteobacterium belonging to a new genus. Teixobactin binds the lipid-pyrophosphate-sugar moiety of lipid II, precursor of peptidoglycan, and lipid III, precursor of wall teichoic acid in gram-positive bacteria. Since its targets do not mutate, there is no resistance development to teixobactin. Sophisticated resistance mechanisms such as destruction of the antimicrobial usually originate in the producing organisms, but E. terrae is a gramnegative bacterium that protects itself by exporting teixobactin across its outer membrane, and there is no such resistance mechanism for the targeted gram-positive organisms to borrow. It appears that teixobactin evolved to be essentially free of resistance. The discovery of teixobactin challenges the dogma of inevitable resistance. Kim Lewis is University Distinguished Professor and Director, Antimicrobial Discovery Center, Northeastern University, Boston, Mass. 
